Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BiPar Sciences has announced the expansion of Phase II clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past six months, expanding on on-going trials in breast and brain cancer.
Subscribe to our email newsletter
The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enroll patients who have a mutation in their BRCA1 or BRCA2 genes.
The company is currently conducting a Phase II trial of BSI-201 in triple- negative breast cancer and is collaborating with the New Approaches to Brain Tumor Therapy consortium, a National Cancer Institute-funded research group, to test BSI-201 in glioblastoma multiforme, the most common brain cancer in adults. An additional trial in uterine cancer is expected to begin enrollment in the coming weeks.
Barry Sherman, executive vice president of Development at BiPar, said: “We will soon have patients enrolled in four separate Phase II trials of BSI-201, reflecting the breadth of tumor types that could be sensitive to the drug.”